PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 104 filers reported holding PHATHOM PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 0.20 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $137 | -11.6% | 13,235 | +22.4% | 0.00% | – |
Q2 2023 | $155 | +74.2% | 10,813 | -13.7% | 0.00% | – |
Q1 2023 | $89 | -11.0% | 12,526 | +41.1% | 0.00% | – |
Q4 2022 | $100 | -99.1% | 8,879 | +809.7% | 0.00% | – |
Q3 2022 | $11,000 | -72.5% | 976 | -79.5% | 0.00% | – |
Q2 2022 | $40,000 | -57.4% | 4,767 | -31.6% | 0.00% | – |
Q1 2022 | $94,000 | – | 6,967 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Medicxi Ventures Management (Jersey) Ltd | 3,760,869 | $39,000,212 | 12.45% |
Frazier Life Sciences Management, L.P. | 10,109,279 | $104,833,223 | 6.96% |
Decheng Capital Management III (Cayman), LLC | 850,000 | $8,814,500 | 2.94% |
Carlyle Group Inc. | 3,496,808 | $36,191,963 | 1.57% |
Ghost Tree Capital, LLC | 395,000 | $4,096,150 | 1.35% |
Newtyn Management, LLC | 500,000 | $5,185,000 | 1.28% |
Altium Capital Management LP | 220,000 | $2,281,400 | 1.19% |
StepStone Group LP | 422,085 | $4,377,021 | 0.98% |
MPM BioImpact LLC | 347,332 | $3,601,833 | 0.96% |
NEA Management Company, LLC | 1,276,595 | $12,238,290 | 0.94% |